GMP Manufacturing

Designed with flexibility, scalability, and compliance in mind, our GMP facility supports the full spectrum of cell and gene therapy modalities. Featuring dedicated manufacturing suites, Fill Finish areas, and QC laboratories, the facility ensures an end-to-end manufacturing solution under one roof.

For companies in early-phase trials, our GMP clinical manufacturing capabilities provide scalable solutions with a focus on process robustness, regulatory compliance, and seamless technology transfer. Whether manufacturing autologous, allogeneic, or viral vector-based therapies, we offer the expertise and infrastructure to support successful clinical progression.

With future-ready capacity and scalable GMP solutions, our commercial manufacturing services support clients moving into late-stage and commercial production. Our 12,000ft² (1,100m²) expansion space is designed to accommodate larger batch production, supporting 500–1000L viral vector processes, RNA, Lipid Nanoparticles (LNPs), and other advanced technologies.

We offer GMP-compliant cell bank production as a standalone service or as part of a wider manufacturing programme. With experience in banking iPSCs, MSCs, and HEK293s, our services include 2D/3D expansion, validated cryopreservation, secure storage, and full QC testing and documentation.

Our dedicated fill finish module includes Grade C cleanroom space and a closed Grade A isolator system. We support clinical vial and bag filling for viral vectors and allogeneic therapies, offering standalone or integrated fill finish with full QA oversight and sterility assurance.

Our in-house QPs and regulatory specialists offer proactive quality oversight and GMP support, from documentation and batch release to audit readiness and training. We ensure compliance is embedded at every stage of your manufacturing journey.